We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.


OncoHost To Present Poster Demonstrating PROphet®’s Application in Multiple Cancer Indications at ASCO 2024

Cancer cells.
Credit: iStock.
Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: 1 minute

OncoHost, announced that it has been accepted for a poster presentation at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting, to be held from May 31 to June 4, 2024, in Chicago, Illinois. The presentation will highlight the ability of the company's PROphet® platform to predict clinical benefit from immune checkpoint inhibitor (ICI)-based therapies across various cancer indications.


“ICIs represent a key treatment modality for a growing number of cancer types, but a gap exists in the availability of predictive tests that can accurately identify patients likely to benefit from these therapies. Our PROphet® platform offers a solution,” said Ofer Sharon, MD, CEO at OncoHost. “This research highlights the adaptability of PROphet® as we work to provide treatment guidance for multiple indications. I am proud of our team’s commitment to improving outcomes for cancer patients worldwide and the ongoing impact of our work in the oncology field.”

Want more breaking news?

Subscribe to Technology Networks’ daily newsletter, delivering breaking science news straight to your inbox every day.

Subscribe for FREE

PROphet® is a novel and robust predictive computational model that analyzes and identifies proteomic profiles in pre-treatment blood plasma by combining bioinformatics, system biology, proteomic pattern recognition and machine learning. PROphetNSCLC™, the first indication for which the platform was developed, predicts clinical benefit from first-line PD-1/PD-L1 inhibitor-based therapies in patients with metastatic non-small cell lung cancer (mNSCLC), offering guidance in choosing between ICI monotherapy and ICI-chemotherapy combination.


For this observational study, pre-treatment plasma samples and clinical data were collected from patients with metastatic melanoma and HPV-related cancers undergoing treatment with PD-1/PD-L1 inhibitor-based therapies. HPV-related cancers included anogenital squamous cell carcinoma, cervical carcinoma, and head and neck squamous cell carcinoma. The presentation will showcase the findings which demonstrate the potential of the PROphetNSCLC™ test in predicting ICI response for indications beyond just NSCLC, underscoring the promise of PROphet® in advancing precision medicine.


The study was conducted in collaboration with Sidney Kimmel Medical College at Thomas Jefferson University, Yale School of Medicine, and the Center for Immuno-Oncology, Center for Cancer Research of the National Cancer Institute.


"We are excited to present our latest findings at ASCO 2024,” said Itamar Sela, Ph.D., VP R&D at OncoHost and co-author of the study. “This study showcases the versatility of the PROphet® platform in predicting benefit from immune-checkpoint inhibitors not only in NSCLC, but also in melanoma and HPV-related cancers. By leveraging the power of plasma-based proteomic analysis, PROphet® offers a non-invasive and efficient method to guide treatment decisions and optimize patient care.”